Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Chronic Pain Treatment Pipeline Review H2 2016

Friday, October 14, 2016 5:46
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Chronic Pain – Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685910-chronic-pain-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Pain 
- The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects 
- The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Pain 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685910-chronic-pain-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 8 
List of Figures 10 
Introduction 11 
Global Markets Direct Report Coverage 11 
Chronic Pain Overview 12 
Therapeutics Development 13 
Pipeline Products for Chronic Pain – Overview 13 
Pipeline Products for Chronic Pain – Comparative Analysis 14 
Chronic Pain – Therapeutics under Development by Companies 15 
Chronic Pain – Therapeutics under Investigation by Universities/Institutes 22 
Chronic Pain – Pipeline Products Glance 23 
Late Stage Products 23 
Clinical Stage Products 24 
Early Stage Products 25 
Unknown Stage Products 26 
Chronic Pain – Products under Development by Companies 27 
Chronic Pain – Products under Investigation by Universities/Institutes 35 
Chronic Pain – Companies Involved in Therapeutics Development 36 
AbbVie Inc 36 
Acadia Pharmaceuticals Inc. 37 
Adynxx, Inc. 38 
Allergan Plc 39 
Amorsa Therapeutics Inc. 40 
arGEN-X BV 41 
Asana BioSciences, LLC 42 
AskAt Inc. 43 
Astraea Therapeutics, LLC 44 
Axsome Therapeutics, Inc. 45 
BioDelivery Sciences International, Inc. 46 
Biogen Inc 47 
Bionomics Limited 48 
Camurus AB 49 
Cara Therapeutics, Inc. 50 
Centrexion Therapeutics Corp 51 
ChironWells GmbH 52 
Collegium Pharmaceutical, Inc. 53 
Crinetics Pharmaceuticals, Inc. 54 
Cyclenium Pharma, Inc. 55 
Cytogel Pharma, LLC 56 
Daewoong Pharmaceutical Co., Ltd. 57 
Daiichi Sankyo Company, Limited 58 
Dompe Farmaceutici S.p.A. 59 
Echo Pharmaceuticals B.V. 60 
Egalet Corporation 61 
Eli Lilly and Company 62 
Elite Pharmaceuticals, Inc. 63 
Glenmark Pharmaceuticals Ltd. 64 
Grunenthal GmbH 65 
Heron Therapeutics, Inc. 66 
INSYS Therapeutics, Inc. 67 
Johnson & Johnson 68 
Kareus Therapeutics, SA 69 
KPI Therapeutics, Inc. 70 
Kymab Limited 71 
Laboratorios Del Dr. Esteve S.A. 72 
Lohocla Research Corporation 73 
Lpath, Inc. 74 
MD Biosciences GmbH 75 
Merck & Co., Inc. 76 
Moberg Pharma AB 77 
Mundipharma International Ltd 78 
Nanomerics Ltd 79 
Nektar Therapeutics 80 
Neura Therapeutik, LLC 81 
Orion Oyj 82 
Pacira Pharmaceuticals, Inc. 83 
Pain Therapeutics, Inc. 84 
PeriphaGen, Inc. 85 
Pfizer Inc. 86 
Phosphagenics Limited 87 
Prismic Pharmaceuticals, Inc. 88 
Purdue Pharma LP 89 
Relmada Therapeutics, Inc. 90 
Ribomic Inc. 91 
Sea4Us 92 
Shulov Innovative Science Ltd. 93 
Synactix Pharmaceuticals, Inc. 94 
Syntrix Biosystems, Inc. 95 
Teva Pharmaceutical Industries Ltd. 96 
Therapix Biosciences Ltd. 97 
Trevena, Inc. 98 
Voyager Therapeutics, Inc. 99 
Yooyoung Pharmaceutical Co., Ltd. 100 
Zynerba Pharmaceuticals, Inc. 101 
Chronic Pain – Therapeutics Assessment 102 
Assessment by Monotherapy Products 102 
Assessment by Combination Products 103 
Assessment by Target 104 
Assessment by Mechanism of Action 111 
Assessment by Route of Administration 118 
Assessment by Molecule Type 120 
Drug Profiles 122 
(celecoxib + tramadol hydrochloride) – Drug Profile 122 
(hydrocodone bitartrate + palmidrol) – Drug Profile 124 
(morphine sulfate + palmidrol) – Drug Profile 125 
(naltrexone hydrochloride + oxycodone hydrochloride) SR – Drug Profile 126 
(oxycodone hydrochloride + palmidrol) – Drug Profile 127 
(palmidrol + pregabalin) – Drug Profile 128 
A-200 – Drug Profile 129 
AGN-XX – Drug Profile 130 
AGN-YY – Drug Profile 131 
AMS-520 – Drug Profile 132 
ASN-008 – Drug Profile 133 
AVLX-144 – Drug Profile 134 
AXS-06 – Drug Profile 135 
AYX-1 – Drug Profile 136 
AYX-2 – Drug Profile 138 
BBI-11008 – Drug Profile 139 
bupivacaine – Drug Profile 140 
bupivacaine hydrochloride – Drug Profile 142 
buprenorphine hydrochloride – Drug Profile 144 
buprenorphine hydrochloride depot – Drug Profile 146 
buprenorphine hydrochloride ER – Drug Profile 147 
buprenorphine hydrochloride long acting – Drug Profile 149 
cebranopadol – Drug Profile 150 
cetirizine hydrochloride + cromolyn sodium – Drug Profile 153 
cetuximab – Drug Profile 154 
CNTX-0290 – Drug Profile 160 
CNV-3000164 – Drug Profile 161 
CNV-3000223 – Drug Profile 162 
CR-4056 – Drug Profile 163 
CR-701 – Drug Profile 164 
CRB-0089 – Drug Profile 165 
Cyt-1010 – Drug Profile 166 
dexmedetomidine hydrochloride – Drug Profile 168 
DF-2593A – Drug Profile 170 
difelikefalin – Drug Profile 171 
dronabinol – Drug Profile 178 
DS-1971 – Drug Profile 180 
DWJ-208 – Drug Profile 181 
ECP-1014 – Drug Profile 182 
Egalet-003 – Drug Profile 183 
fluticasone propionate – Drug Profile 184 
FY-101C – Drug Profile 185 
FY-103B – Drug Profile 186 
GBR-900 – Drug Profile 187 
Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain – Drug Profile 188 
grapiprant – Drug Profile 189 
HPI-201 – Drug Profile 191 
HS-731 – Drug Profile 192 
hydrocodone bitartrate ER – Drug Profile 193 
hydrocodone bitartrate ER – Drug Profile 196 
hydrocodone bitartrate ER – Drug Profile 197 
hydromorphone hydrochloride – Drug Profile 198 
Kindolor – Drug Profile 199 
KY-1017 – Drug Profile 200 
L-779976 – Drug Profile 201 
lacosamide – Drug Profile 202 
LEVI-04 – Drug Profile 203 
levorphanol tartrate ER – Drug Profile 204 
Lpathomab – Drug Profile 206 
MD-354 – Drug Profile 209 
Monoclonal Antibodies for Chronic Pain – Drug Profile 210 
Monoclonal Antibodies to Block Nav1.7 for Chronic Pain – Drug Profile 211 
morphine sulfate ER – Drug Profile 212 
MR-309 – Drug Profile 216 
NET-END – Drug Profile 218 
NKTR-181 – Drug Profile 219 
NL-001 – Drug Profile 222 
NL-002 – Drug Profile 223 
NM-0127 – Drug Profile 224 
Omnitram – Drug Profile 225 
onabotulinumtoxin A – Drug Profile 226 
OSX-300 – Drug Profile 231 
OSX-300 Backups – Drug Profile 232 
oxycodone hydrochloride ER – Drug Profile 233 
oxycodone hydrochloride ER – Drug Profile 236 
oxycodone hydrochloride ER – Drug Profile 237 
oxymorphone hydrochloride – Drug Profile 239 
oxymorphone hydrochloride ER – Drug Profile 240 
PAC-CP – Drug Profile 241 
palmidrol – Drug Profile 242 
Peptide to Block Cav2.2 for CNS Disorders – Drug Profile 243 
Peptides to Inhibit Ion Channel for Chronic Pain – Drug Profile 244 
Peptides to Target TRPV1 for Pain and Itch – Drug Profile 245 
PN-6047 – Drug Profile 246 
PRC-062 – Drug Profile 247 
Prostatic Acid Phosphatase – Drug Profile 248 
PspTx-3 – Drug Profile 249 
raxatrigine hydrochloride – Drug Profile 250 
RBM-005 – Drug Profile 253 
REL-1017 – Drug Profile 254 
SAFit2 – Drug Profile 257 
Small Molecule for Chronic Pain – Drug Profile 258 
Small Molecule for Chronic Pain – Drug Profile 259 
Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain – Drug Profile 260 
Small Molecule to Antagonize GPR-84 for Chronic Pain – Drug Profile 261 
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders – Drug Profile 262 
Small Molecule to Block Nav1.9 Channel for Pain – Drug Profile 264 
Small Molecule to Inhibit ASK-1 for Chronic Pain – Drug Profile 265 
Small Molecule to Inhibit mPGES-1 for Chronic Pain – Drug Profile 266 
Small Molecules for Chronic Wound Pain – Drug Profile 267 
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder – Drug Profile 268 
Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain – Drug Profile 269 
Small Molecules to Agonize CB2 for Chronic Pain and Migraine – Drug Profile 270 
Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain – Drug Profile 271 
Small Molecules to Agonize NOP for Pain and Alcohol Addiction – Drug Profile 272 
Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain – Drug Profile 273 
Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain – Drug Profile 274 
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System – Drug Profile 275 
Small Molecules to Block Cav2.2 Channel for Chronic Pain – Drug Profile 276 
Small Molecules to Block Cav2.2 Channel for Chronic Pain – Drug Profile 277 
Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain – Drug Profile 278 
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain – Drug Profile 279 
Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System – Drug Profile 280 
Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain – Drug Profile 281 
Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain – Drug Profile 282 
Small Molecules to Inhibit DAAO for Chronic Pain – Drug Profile 283 
Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain – Drug Profile 284 
Small Molecules to Target Opioid Receptors for Chronic Pain – Drug Profile 285 
SYN-003 – Drug Profile 286 
Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain – Drug Profile 287 
tanezumab – Drug Profile 288 
tapentadol hydrochloride IR – Drug Profile 291 
TRV-734 – Drug Profile 293 
U-2902 – Drug Profile 295 
UMB-425 – Drug Profile 297 
Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain – Drug Profile 298 
VM-902A – Drug Profile 299 
VYNAV-01 – Drug Profile 300 
XT-101 – Drug Profile 301 
YYC-301 – Drug Profile 302 
ZEP-3 – Drug Profile 303 
ZYN-001 – Drug Profile 304 
Chronic Pain – Dormant Projects 305 
Chronic Pain – Discontinued Products 314 
Chronic Pain – Product Development Milestones 317 
Featured News & Press Releases 317 
Appendix 325 
Methodology 325 
Coverage 325 
Secondary Research 325 
Primary Research 325 
Expert Panel Validation 325 
Contact Us 325 
Disclaimer 326

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685910

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.